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Research
Inorganic As (iAs) is one of the most potent 
environmental carcinogens [International 
Agency for Research on Cancer (IARC) 1987]. 
However, chronic exposures to iAs have also 
been associated with various non  cancerous dis-
eases, including diabetes mellitus. Increased 
risks of diabetes have been reported in popula-
tions exposed to high levels of iAs in drinking 
water and among workers exposed to iAs in 
occupational settings (Navas-Acien et al. 2006). 
Although results of epidemiologic studies   
examining effects of low exposures to iAs 
have been inconclusive, laboratory research 
has shown that exposures to iAs can produce 
effects that are consistent with diabetes (Navas-
Acien et al. 2006; Paul et al. 2007b). 
We previously examined associations 
between iAs exposure and diabetes both in 
population-based studies and in labora-
tory studies, using tissue culture and animal 
models. Our laboratory studies have focused 
on effects of iAs and its metabolites on the 
insulin-activated signal transduction pathway 
that regulates the insulin-dependent glucose 
uptake in peripheral tissues. We found that 
trivalent metabolites of iAs—arsenite (iAsIII), 
methyl  arsonite (MAsIII), and dimethyl-
arsinite (DMAsIII)—inhibit insulin signaling 
and insulin-stimulated glucose uptake by cul-
tured 3T3-L1 adipocytes at concentrations 
that do not affect cell viability (Walton et al. 
2004). Specifically, iAsIII and MAsIII inhibited 
insulin-dependent phosphorylation of protein 
kinase B (PKB/Akt), thus preventing trans-
location of GLUT4 (insulin-sensitive glucose 
transporter) from the peri  nuclear compartment 
of adipocytes to the plasma membrane (Paul 
et al. 2007a). In contrast, DMAsIII inhibited 
GLUT4 translocation by interfering with 
signaling steps downstream from PKB/Akt.   
We also examined diabeto  genic effects of 
iAs exposure in mice (Paul et al. 2007b). In 
that study, weanling male C57BL/6 mice fed 
a regular labora  tory chow drank for 8 weeks 
either deionized water (diH2O) or diH2O with 
addition of iAsIII at concentrations of 25 or 
50 ppm As. Intraperitoneal glucose tolerance 
tests revealed impaired glucose tolerance in 
mice exposed to 50 ppm As but not in mice 
drinking diH2O with 25 ppm As or pure 
diH2O (Paul et al. 2007b). Notably, the aver-
age concentration of total speciated As in livers 
from mice in the 50-ppm group was compa-
rable to the highest concentration of total As 
reported in livers of residents of Bangladesh 
who had consumed water with order of mag-
nitude lower levels of iAs (Mazumder 2005). 
These data suggest that mice are less suscepti-
ble than humans to the diabetogenic effects of 
chronic exposure to iAs, possibly due to a more 
efficient clearance of iAs or its metabolites 
from target tissues, and that concentrations of 
iAs higher than those found in drinking water 
should be used in laboratory studies to repro-
duce the diabetogenic effects of iAs exposure 
reported in human populations.
In the present study, we examined inter-
actions of iAs exposure with obesity, the lead-
ing cause of diabetes worldwide. Our results 
suggest that the key charac  teris  tics of diabetes 
produced in mice by an obeso  genic diet com-
bined with chronic exposure to iAs [normal 
fasting blood glucose (FBG) and normal fast-
ing serum insulin (FSI) levels with pronounced 
glucose intolerance] differ from those described 
for type 2 diabetes. Thus, iAs exposure may 
target tissues or regulatory mechanisms that are 
not typically associated with type 2 diabetes.
Materials and Methods
Chemicals. Sodium arsenite, sodium salt 
(99% pure), was purchased from Sigma-
Aldrich (St. Louis, MO). Ultrapure phos-
phoric acid was obtained from J.T. Baker 
(Phillipsburg, NJ). Sodium arsenate (iAsV), 
sodium salt (96%; Sigma-Aldrich); methyl-
arsonate (MAsV), disodium salt (98%; Chem 
Service, West Chester, PA); and dimethyl-
arsinic acid (DMAsV; 98%; Strem Chemicals, 
Inc., Newburyport, MA) were used as stan-
dards for speciation analysis of As in mouse 
tissues. All other chemicals were of the high-
est grade commercially available.
Mice. Four-week-old male weanling 
C57BL/6 mice were obtained from the 
Jackson Laboratory (Bar Harbor, ME) and 
housed in the University of North Carolina–
Chapel Hill (UNC-CH) Animal Facility, 
which is fully accredited by the American 
Association for Accreditation of Laboratory 
Animal Care. Mice were housed five per cage 
in poly  carbonate cages with corncob bed-
ding in controlled conditions (12-hr light/
dark cycle, 22 ± 1°C, and 50 ± 10% humid-
ity). Mice were fed a low-fat diet (LFD; 11% 
fat) or a high-fat diet (HFD; 58% fat; both 
from Research Diets, Inc., Brunswick, NJ) 
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Ba c k g r o u n d: Type 2 diabetes is characterized by glucose intolerance and insulin resistance. 
Obesity is the leading cause of type 2 diabetes. Growing evidence suggests that chronic exposure to 
inorganic arsenic (iAs) also produces symptoms consistent with diabetes. Thus, iAs exposure may 
further increase the risk of diabetes in obese individuals.
oBjectives: Our goal was to characterize diabetogenic effects of iAs exposure and high-fat diet 
(HFD) in weaned C57BL/6 mice.
Me t h o d s : Mice were fed HFD or low-fat diet (LFD) while exposed to iAs in drinking water (25 or 
50 ppm As) for 20 weeks; control HFD and LFD mice drank deionized water. Body mass and 
adiposity were monitored throughout the study. We measured glucose and insulin levels in fasting 
blood and in blood collected during oral glucose tolerance tests (OGTT) to evaluate the diabeto-
genic effects of the treatment.
re s u l t s: Control mice fed HFD accumulated more fat, had higher fasting blood glucose, and were 
more insulin resistant than were control LFD mice. However, these diabetes indicators decreased 
with iAs intake in a dose-dependent manner. OGTT showed impaired glucose tolerance for both 
control and iAs-treated HFD mice compared with respective LFD mice. Notably, glucose intoler-
ance was more pronounced in HFD mice treated with iAs despite a significant decrease in adiposity, 
fasting blood glucose, and insulin resistance.
co n c l u s i o n s: Our data suggest that iAs exposure acts synergistically with HFD-induced obesity 
in producing glucose intolerance. However, mechanisms of the diabetogenic effects of iAs exposure 
may differ from the mechanisms associated with the obesity-induced type 2 diabetes.
key w o r d s : arsenic, diabetes, diet-induced obesity, glucose intolerance, high-fat diet, insulin resistance. 
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and drank either diH2O or diH2O plus iAsIII 
(25 or 50 ppm As). Water containing iAsIII 
was freshly prepared every 3–4 days to mini-
mize oxidation of iAsIII to iAsV. Water and 
food consumption and body mass were moni-
tored in all exposure groups every week. Body 
composition was measured biweekly at the 
UNC-CH Nutrition Obesity Research Core, 
using EchoMRI-100 (EchoMRI, Houston, 
TX). The animals were treated humanely and 
with regard for alleviation of suffering. All 
procedures involving mice were approved by 
the UNC-CH Institutional Animal Care and 
Use Committee.
Oral glucose tolerance test (OGTT) and 
analyses of blood glucose and insulin. After 
20 weeks, both control and iAs-treated LFD 
and HFD mice were fasted overnight before 
adminis  tra  tion of OGTT. d-Glucose (Sigma) 
was dissolved in diH2O and orally admin-
istered to the fasted mice (2 g/kg of body 
weight) using a 20-gauge stainless steel gavage 
feeding needle (Fisher Scientific, Waltham, 
MA). Samples of whole blood (2–3 μL each) 
were collected from a tail-clip bleed immedi-
ately before and 15, 30, 60, 90, and 120 min 
after glucose administration. Blood glucose 
levels were measured using a Freestyle Glucose 
Monitoring System (Abbott Laboratories, 
Abbott Park, IL). Additional samples of whole 
venous blood (100 μL) were collected from 
tails immediately before and 15 min after 
glucose adminis  tration for determination of 
serum insulin levels. The blood was allowed 
to clot on ice for 15 min and then centrifuged 
(200 × g) at 4°C for 10 min. 
Serum was analyzed using the Rat/Mouse 
Insulin ELISA kit according to the manufac-
turer’s protocol (Millipore, Billerica, MA). We 
used the FBG and FSI concentrations to calcu-
late the homeo  stasis model assessment–insulin 
resistance (HOMA-IR) value: 
HOMA-IR =  
[FSI (in microunits per milliliter)  
× FBG (in millimoles per liter)]  
÷ 22.5.
The blood glucose and serum insulin levels 
recorded during OGTT were used to evaluate 
glucose tolerance and insulin response to glu-
cose challenge, respectively. After OGTT, mice 
were returned to their cages and treatment 
continued for 7–10 days before necropsy.
Blood and tissue collection at necropsy. 
Whole blood samples were collected by sub-
mandibular bleeds, and mice were sacrificed 
by cervical dislocation. Hematocrit (a marker 
of dehydration) was determined in samples of 
fresh blood (~ 100 μL) using 40-mm heparin-
coated capillary tubes. Capillary tubes were 
centrifuged at 12,000 rpm in a micro  hemato-
crit centrifuge (Unico, Dayton NJ) for 15 min, 
and the percentage of red blood cells was 
recorded for each mouse. Serum was isolated 
from sub  mandibular blood as described above. 
Liver, inguinal adipose tissue, quadriceps, and 
pancreas were collected during necropsy and 
snap frozen in liquid nitrogen. Serum and 
the tissue samples were stored at –80°C until 
analysis.
Analyses of hepatic and serum triacyl­
glycerol. We measured triacyl  glycerol (TAG) 
contents in serum and in liver homogenates 
spectrophotometrically (at 490 nm) after a 
two-step extraction in a chloroform/methanol 
(2:1) mixture and in pure chloroform, using a 
Stanbio Enzymatic Triglyceride Kit (Stanbio, 
Boerne, TX), following the manufacturer’s 
instructions.
Speciation analysis of As in tissues. For 
analysis of iAs metabolites, 10% (wt/vol) tis-
sue homogenates were prepared in diH2O 
and digested in ultra  pure phosphoric acid. 
Concentrations of As species were determined 
in digested homogenates by hydride genera-
tion–cryotrapping–atomic absorption spec-
trometry (HG-CT-AAS), following previously 
described procedures (Hernández-Zavala et al. 
2008). This method detects and quantifies total 
iAs (iAsIII + iAsV), total MAs (MAsIII + MAsV), 
and total DMAs (DMAsIII + DMAsV).
Statistical analysis. Results of the analy-
ses are expressed as mean ± SE for each treat-
ment group (n = 6–10). Effects of diet and iAs 
exposure, as well as inter  actions between diet 
and iAs exposure, were analyzed by analysis of 
covariance. Differences between the treatment 
groups were evaluated by one-way analysis of 
variance with Tukey or Bonferroni multiple-
comparison post  tests. All statistical analyses 
were performed using Graphpad Prism (ver-
sion 5.0; GraphPad Software, San Diego, CA). 
Differences among means with p < 0.05 were 
considered statistically significant.
Results
Water, As, food, and calorie intakes. The daily 
water, food, and calorie intakes were signifi-
cantly affected by type of diet and iAs exposure 
(Figure 1). Control mice on HFD consumed 
significantly less water than did control mice 
on LFD (2.86 and 4.21 mL/day, respectively). 
Consistent with our previous results (Paul 
et al. 2007b), water intake decreased in both 
groups exposed to iAs (Figure 1A); LFD and 
HFD mice exposed to 25 ppm As drank 2.49 
and 2.28 mL/day compared with mice in the 
respective 50-ppm groups that drank 1.68 and 
1.74 mL/day. We used hematocrits to charac-
terize the hydration status of the mice in all 
treatment groups [see Supplemental Material, 
Figure 1 (doi:10.1289/ehp.1003324)]. We 
found no significant differences, suggesting 
that the lower water intakes associated with 
consumption of HFD or iAs treatment did 
not cause dehydration. The average daily As 
intakes were estimated from water intake. 
Mice on LFD and HFD exposed to 25 ppm 
As ingested 62.2 and 57.1 μg/day As, respec-
tively; mice on LFD and HFD exposed to 
50 ppm As ingested 82.5 and 86.8 μg/day As, 
Figure 1. Intakes of water (A), As (B), food (C), and calories (D) by control mice or mice exposed to 25 or 
50 ppm As and fed LFD or HFD (mean ± SE; n = 38 for A and B; n = 17 for C and D). 
Values marked with the same letters are statistically significantly different: (A) for a–g, p < 0.001; (C) for d and f, p < 0.01; 
and for a–c and e, p < 0.001; (D), for b, p < 0.01; and for a and c, p < 0.001. 
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respectively (Figure 1B). In general, mice on 
LFD consumed more food than did mice on 
HFD (Figure 1C): mice in the LFD groups 
consumed 2.85 g/day (controls), 3.04 g/day 
(25 ppm As), and 2.71 g/day (50 ppm As) 
compared with mice in the HFD groups, 
which consumed 2.41 g/day (controls), 2.31 
g/day (25 ppm As), and 2.22 g/day (50 ppm 
As). We estimated calorie intakes for mice 
in the treatment groups using food intake 
data and caloric densities of LFD and HFD 
(Figure 1D). Exposure to iAs led to a small 
decrease in calorie intake in the HFD group: 
13.4 calories/day for controls, 12.9 calories/day   
for 25 ppm As, and 12.4 calories/day for 
50 ppm As. However, these differences were 
not statistically significant.
Body mass and composition. Figure 2 
shows body mass and body composition for 
control and iAs-treated mice fed LFD and 
HFD. As expected, control mice fed HFD 
for 20 weeks accumulated significantly more 
fat and weighed more than the control mice 
on LFD. However, iAs exposure decreased 
both the HFD-induced weight gain and fat 
accumulation. Specifically, the mice fed HFD 
and exposed to 25 and 50 ppm As weighed 
less (42.6 and 33.9 g) and had less fat mass 
(16.7 and 9.4 g) than did the HFD controls 
(47.9 g body mass and 22.0 g fat mass). The 
differences in both total body mass and fat 
mass were statistically significant. Notably, iAs 
exposure had no statistically significant effects 
on lean mass of mice in the HFD group. iAs 
exposure had no effect on fat mass in LFD 
mice; however, lean mass decreased by 9% in 
LFD mice exposed to 50 ppm As compared 
with controls (p < 0.05).
Liver adiposity and serum TAG concen­
tration. The average total liver mass was sig-
nificantly greater in control mice on HFD 
compared with LFD controls (Figure 3A). 
However, iAs exposure substantially reduced 
or eliminated the difference in liver mass 
between HFD and LFD mice. To deter-
mine whether these effects are associated with 
differences in fat accumulation, we compared 
TAG concentrations in the livers of mice in 
all treatment groups (Figure 3B). The aver-
age TAG concentration was > 2-fold higher 
in the livers of HFD controls compared with 
LFD controls. The difference in the hepatic 
TAG concentrations remained statistically 
significant for HFD and LFD mice exposed 
to 25 ppm As but not for the mice exposed 
to 50 ppm As. This was in part because the 
exposure to iAs increased TAG concentra-
tion in a concentration-dependent manner 
in livers of mice fed LFD; we noted a statisti-
cally significant elevation in liver TAG for 
LFD mice exposed to 50 ppm As compared 
with LFD controls (p < 0.05). We also meas-
ured TAG concentrations in serum of fasted 
mice from all treatment groups (Figure 3C). 
In general, consumption of HFD was associ-
ated with higher serum TAG levels. However, 
iAs exposure lowered serum TAG in the LFD 
groups and particularly the HFD groups in a 
concentration-dependent manner. As a result, 
we observed no statistically significant differ-
ence in serum TAG levels between the LFD 
and HFD mice exposed to 50 ppm As.
Glucose tolerance. We used FBG and 
2-hr OGTT to evaluate glucose homeo-
stasis and tolerance (Figure 4). The control 
mice fed LFD had an average FBG level of 
79 mg/dL. The consumption of HFD for 
20 weeks resulted in a statistically significant 
increase in FBG in control mice: 165 mg/dL 
(p < 0.05) (Figure 4A). However, we detected 
lower FBG levels in HFD mice exposed to 
25 and 50 ppm As: 128 and 117 mg/dL, 
respectively (Figure 4B,C). The differences in 
FBG between the HFD control and the HFD 
iAs-treated mice were statistically significant 
(p < 0.05). The exposure to iAs had no signifi-
cant effects on FBG in the LFD group. For all 
mice, regardless of diet or iAs exposure, OGTT 
showed the charac  teristic rapid rise in blood 
glucose, peaking within 15–30 min of glucose 
challenge. This peak was followed by a gradual 
decrease, indicative of the uptake of glucose 
by liver and peripheral tissues. Blood glucose 
levels in LFD groups peaked at approximately 
350 mg/dL and approached baseline levels by 
120 min after glucose challenge, whereas HFD 
groups peaked at approximately 400 mg/dL 
and remained elevated compared with LFD 
groups (Figure 4A–C). To quantify glucose tol-
erance, we calculated the area under the OGTT 
curve (AUC) for all treatment groups. AUC 
values were significantly higher for mice fed 
HFD than for mice fed LFD regardless of the 
iAs exposure (Figure 4D). The average AUC 
values were higher for HFD mice exposed to 
25 and 50 ppm As (35,315 and 38,625 units, 
respectively) compared with HFD controls 
(34,847 units). However, the differences did 
not reach statistical significance.
Figure 2. Body mass and body composition (mean ± SE) of control mice or mice exposed to 25 or 50 ppm 
As and fed LFD or HFD (n = 9–10). (A) Total body mass. (B) Lean and fat mass. 
Values marked with the same letters are statistically significantly different: (A) for e, p < 0.05; for c and f, p < 0.01; and for 
a, b, and d, p < 0.001; (B) for d, g, and h, p < 0.05; for c and f, p < 0.01; and for a, b, e, and i, p < 0.001. 
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Insulin resistance. We measured FSI and 
serum insulin at 15 min into OGTT (15SI) to 
charac  terize insulin secretion in response to the 
glucose challenge and insulin resistance. Both 
FSI and 15SI levels were affected by HFD and 
exposure to iAs (Figure 5). In general, mice in 
the HFD groups had elevated FSI and 15SI 
levels compared with mice in the LFD groups. 
However, FSI and 15SI values in HFD mice 
decreased with iAs exposure in a concentration-
dependent manner, resulting in near-normal 
values for HFD mice exposed to 50 ppm As. 
We found no statistically significant effects of 
iAs exposure on FSI or 15SI in the LFD group. 
We used FBG and FSI values to calculate 
HOMA-IR, an indicator of insulin resistance. 
The average HOMA-IR values were consistently 
higher in HFD than in LFD groups (Figure 6). 
iAs exposure did not change HOMA-IR in 
mice fed LFD, but it decreased HOMA-IR in 
the HFD group in a concentration-dependent 
manner, thus reducing the difference between 
the mice in HFD and LFD groups. The aver-
age HOMA-IR value was 5 times higher in 
control HFD than in control LFD mice, but 
only 3 times and 2.5 times higher in HFD 
versus LFD mice exposed to 25 and 50 ppm 
As, respectively.
Tissue distribution of iAs metabolites. We 
used HG-CT-AAS to determine concentra-
tions of the metabolites of iAs in pancreas and 
in tissues involved in postprandial glucose 
metabolism, including liver, skeletal muscle, 
and fat (Figure 7). Exposure to iAs resulted 
in a concentration-dependent accumulation 
of iAs metabolites in the liver, skeletal mus-
cle, pancreas, and fat of mice on LFD. We 
also found a similar concentration-dependent 
increase in iAs metabolite levels in the muscle 
and pancreas of HFD mice. In contrast, in 
HFD mice exposed to 25 ppm As, liver and fat 
were saturated with iAs metabolites, because 
the concentrations of these metabolites did not 
significantly increase after exposure to 50 ppm. 
For mice in the iAs-treated groups, we found 
the highest concentrations of iAs metabolites 
in the liver, followed by muscle, pancreas, and 
fat. DMAs was the major metabolite detected 
in the tissues of mice exposed to iAs. The tis-
sues of control mice in both LFD and HFD 
groups contained mainly iAs.
Discussion
Both male and female C57BL/6 mice have 
been frequently used in studies examining 
effects of obeso  genic diets, including obesity-
related type 2 diabetes. This mouse strain is 
charac  terized by a low baseline occurrence of 
diabetes and a high susceptibility to diet-in-
duced diabetes (Petro et al. 2004; Surwit et al. 
1988, 1995). Our previous work has shown 
that male C57BL/6 mice are also a good 
animal model for studying the diabeto  genic 
effects of iAs exposure (Paul et al. 2007b). 
When exposed to iAsIII in drinking water 
and fed a regular, grain-based laboratory diet 
(LabDiet, Richmond, IN), these mice devel-
oped glucose intolerance charac  terized by 
abnormally high blood glucose levels after an 
intra  peritoneal injection of glucose. However, 
Figure 4. OGTT results (mean ± SE) for control mice (A) and mice exposed to 25 ppm As (B) or 50 ppm As 
(C) and fed LFD or HFD (n = 9–10). Average FBG values correspond to the values at time 0. (D) AUCs for 
mice fed LFD or HFD. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with LFD mice. Values marked with the same letters are statistically signifi-
cantly different: (D) for a, p < 0.05; for b, p < 0.01; and for c, p < 0.001. 
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the grain-based diet contained 19.5–28.6 ppb 
As (mainly iAs) and was a source of a rela-
tively high background iAs exposure, possibly 
compromising the study design. To avoid this 
problem in the present study, we used only 
purified diets that did not contain grain com-
ponents. The levels of As in these diets were 
below the detection limit of HG-CT-AAS for 
this type of matrix (~ 0.5 ppb). Additional 
information about the previously used grain-
based diet and LFD and HFD used in this 
study is provided in Supplemental Material, 
Table 1 (doi:10.1289/ehp.1003324).
Our OGTT results showed that mice on 
the purified LFD, unlike mice on the grain-
based diet (Paul et al. 2007b), did not develop 
glucose intolerance after exposure to iAs 
(Figure 4). When analyzing this unexpected 
result, we found that the mice fed the purified 
LFD or HFD drank less water than did mice 
in the previous study that were fed the grain-
based diet [see Supplemental Material, Figure 2 
(doi:10.1289/ehp.1003324)]. Consequently, 
the iAs intakes were signifi  cantly lower for the 
LFD and HFD mice in the present study, 
resulting in lower concentrations of As species 
in the target tissues. For example, the mice 
fed the grain-based diet that developed glu-
cose intolerance after exposure to 50 ppm As 
(Paul et al. 2007b) drank, on average, 2.5 mL 
water per day (~ 125 μg/day As); liver and 
pancreas of these mice contained > 1,100 and 
350 ng As/g, respectively. In comparison, the 
LFD mice exposed to 50 ppm As in the pres-
ent study drank only 1.6 mL water per day, 
which represents a daily As intake of 81 μg; the 
average concentrations of As in the liver and 
pancreas were 474 and 138 ng/g, respectively. 
These data suggest that reaching critical thresh-
old concentrations of As in tissues involved in 
the regulation of glucose homeo  stasis is essen-
tial for development of iAs-induced diabetes in 
mice on diets with low fat content. Thus, con-
centrations substantially > 50 ppm As would 
have to be used in the present study to reach 
the critical mass of As metabolites in the target 
tissues and to produce a diabetic pheno  type in 
mice fed the purified LFD.
The main goal of our study was to charac-
terize the diabeto  genic effects of combined 
exposure to iAs and HFD. Specifically, we 
wanted to examine whether mice fed the 
obeso  genic HFD are more susceptible to the 
diabeto  genic effects of chronic exposure to iAs. 
Type 2 diabetes results from a progressive insu-
lin secretory defect on the background of insu-
lin resistance (American Diabetes Association 
2006). Early stages of the disease are charac-
terized by resistance of the liver and peripheral 
tissues to insulin signal, resulting in hyper-
glycemia, hyper  insulinemia, and glucose intol-
erance. Charac  teris  tics of advanced disease are 
failure of the pancreatic β cells to keep up with 
the increasing demand for insulin and a gradual 
decay of β-cell functions. Our findings of high 
FBG, FSI, 15SI, and HOMA-IR in the control 
obese mice fed HFD are consistent with the 
early stages of type 2 diabetes. Fat represented 
> 52% of body mass of the control HFD mice. 
In addition, TAG levels were significantly 
higher in the liver and plasma of these mice 
compared with the LFD controls. The con-
comitant exposure to iAs dramatically changed 
the pheno  type associated with HFD consump-
tion. The HFD mice exposed to 50 ppm As 
accumulated less fat (~ 30% of body mass) 
and had lower plasma TAG than the HFD 
controls. The FBG, FSI, 15SI, and HOMA-IR 
values were significantly lower in the HFD 
group exposed to 50 ppm As than in HFD 
controls. However, glucose intolerance mea-
sured by OGTT remained high and appeared 
even more pronounced than in HFD controls. 
The shape of the OGTT curve also changed, 
showing high blood glucose levels already at 
15–30 min after the glucose dose. This time 
interval is consistent with post  prandial uptake 
of glucose from portal circulation by the liver, 
indicating that hepatic metabolism of glucose 
may be affected by iAs exposure.
This is the first study to show that chronic 
exposure to iAs suppresses diet-induced obe-
sity in laboratory mice. Data collected here do 
not provide information about mechanisms 
under  lying the anti  obesogenic effects of iAs. 
However, previous work has shown that iAsIII 
inhibits signal transduction mechanisms that 
are responsible for adipocyte differentiation 
(Trouba et al. 2000; Wauson et al. 2002). 
Differentiated adipocytes are responsible for fat 
(TAG) accumulation in adipose tissues. Thus, 
it is plausible that the limited fat accumula-
tion in HFD mice exposed to iAs is due to 
the inhibition of adipocyte differentiation by 
iAs or by its trivalent methylated metabo  lites. 
An alternative mechanism could be associ-
ated with impaired TAG synthesis in the liver 
(e.g., as a result of hepatic insulin resistance) 
and decreased secretion of TAG for transport 
to the adipose tissues. The trend for lowering 
hepatic TAG accumulation and the decreased 
plasma TAG levels in the iAs-exposed mice on 
HFD are consistent with this mechanism.
Taken together, our data suggest that iAs 
exposure may act synergistically with HFD-
induced obesity, producing glucose intoler-
ance in mice with a relatively low adiposity. 
Notably, the diabetic pheno  type associated 
with the exposure of HFD mice to iAs dif-
fers from that of typical type 2 diabetes. It 
combines pronounced glucose intolerance 
and a moderately elevated FBG with almost 
normal insulin sensitivity when measured by 
FSI, 15SI, or HOMA-IR. Low FSI, 15SI, 
and HOMA-IR values are generally inter-
preted as indicators of adequate insulin 
Figure 7. Speciation of As in tissues involved in regulation of glucose homeostasis. Mean concentrations 
of iAs, MAs, and DMAs are shown for liver (A), muscle (B), pancreas (C), and adipose tissue (D) from con-
trol mice (CLFD, CHFD) and mice exposed to 25 ppm As (25LFD, 25HFD) or 50 ppm As (50LFD, 50HFD) and 
fed LFD or HFD. For A, B, and D; n = 9–10; for C, n = 5–7. 
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sensitivity. However, low FSI and 15SI val-
ues can also indicate impaired insulin produc-
tion by β cells. With low FSI, the calculated 
HOMA-IR value would also be low, assuming 
that FBG does not increase by a significant 
margin. At the same time, impaired insulin 
production would result in a pronounced glu-
cose intolerance in a manner that is consistent 
with the pheno  type described for the HFD 
mice exposed to 50 ppm As. Recent labora-
tory studies have shown that low, subtoxic 
concentrations of iAsIII can inhibit glucose-
stimulated insulin expression or secretion by 
cultured β cells (Díaz-Villaseñor et al. 2006) 
and a rat insulinoma (INS-1) cell line (Fu 
et al. 2010). Thus, it is possible that both insu-
lin resistance in the liver and peripheral tissues 
and impaired β-cell function determine the 
diabetic pheno  type produced by the combined 
exposure to iAs and HFD. Alternatively, iAs 
exposure could interfere with the production 
or signaling of the incretin hormones glucose-
dependent insulinotropic polypeptide (GIP) 
and glucagon-like peptide-1 (GLP-1) that, 
respectively, induce insulin secretion from 
the pancreatic β cells and suppress glucagon 
release from the α cells during meals.
Using HOMA-IR instead of a direct 
measurement of β-cell function and signals 
regulating this function represents a signifi-
cant limitation for this study. Additional and 
more comprehensive methods (e.g., insulin 
tolerance test, frequently sampled intravenous 
glucose tolerance test, or the hyper  insulinemic 
euglycemic clamp) will be needed in future 
studies to pinpoint the exact mecha  nisms of 
the diabeto  genic effects of iAs exposure alone 
and combined with diet-induced obesity.
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